Bevacizumab
Treatment for Brain And Central Nervous System Cancer
Typical Dosage: 10 mg/kg IV every 2 weeks
Effectiveness
55%
Safety Score
40%
Clinical Trials
117
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg/kg IV every 2 weeks
Time to Effect
1-2 months
Treatment Duration
6-18 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100,000
Monitoring:$5,000
Side Effect Mgmt:$5,000
Total Annual:$110,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$300,000/QALY
QALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$244,444
Comparison vs Lomustine
Cost Difference
+$90,000/year
More expensive
QALY Difference
+0.01 QALYs
Better outcomes
Dominance
No dominance
Bevacizumab Outcomes
for Brain And Central Nervous System Cancer
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+45%
Remission Rate
+1%
Common Side Effects
Hypertension
+35%
Proteinuria
+25%
Thromboembolic events
+15%
Hemorrhage
+7%
GI perforation
+1%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
16 completed trials for Bevacizumab in Brain And Central Nervous System Cancer
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
NCT00337207COMPLETEDPHASE2
55 participants
INTERVENTIONAL
Chicago, United States +1 more
Started: Mar 1, 2006
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00621686COMPLETEDPHASE2
54 participants
INTERVENTIONAL
Scottsdale, United States +203 more
Started: Sep 1, 2008
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00720356COMPLETEDPHASE2
115 participants
INTERVENTIONAL
Los Angeles, United States +8 more
Started: Jul 7, 2009
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
NCT00268359COMPLETEDPHASE2
68 participants
INTERVENTIONAL
Durham, United States
Started: May 1, 2005
Bevacizumab in Recurrent Grade II and III Glioma
NCT01164189COMPLETEDPHASE2
155 participants
INTERVENTIONAL
Linz, Austria +38 more
Started: Feb 1, 2011
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT01013285COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Los Angeles, United States
Started: Jun 1, 2006
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
NCT00352521COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Durham, United States
Started: Apr 1, 2006
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
NCT01931098COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Bethesda, United States
Started: Dec 10, 2015
Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
NCT01332929COMPLETEDPHASE1
21 participants
INTERVENTIONAL
Caen, France +5 more
Started: Jun 1, 2010
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
NCT00832598COMPLETEDNA
13 participants
INTERVENTIONAL
New York, United States
Started: Jan 1, 2009
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
NCT00883688COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Stanford, United States +5 more
Started: Jul 1, 2009
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
NCT01048554COMPLETEDPHASE2
34 participants
INTERVENTIONAL
San Francisco, United States +2 more
Started: Nov 1, 2009
Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
NCT01811498COMPLETEDPHASE1, PHASE2
31 participants
INTERVENTIONAL
New York, United States
Started: Feb 1, 2013
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NCT04446416COMPLETEDNA
6 participants
INTERVENTIONAL
Taoyuan, Taiwan
Started: Jul 21, 2020
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
NCT00463203COMPLETEDPHASE2
54 participants
INTERVENTIONAL
Aalborg, Denmark +2 more
Started: Mar 1, 2007
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
NCT02768389COMPLETEDEARLY_PHASE1
18 participants
INTERVENTIONAL
Cincinnati, United States +3 more
Started: Sep 6, 2016
Showing 20 of 118 total trials